Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
14. März 2019 16:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
19. Februar 2019 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
11. Februar 2019 08:00 ET
|
Allakos Inc.
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU...
Allakos to Host Investor Day on February 19 in New York City
04. Februar 2019 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
29. Januar 2019 08:00 ET
|
Allakos Inc.
-- 82% (9 of 11) response rate in patients with cholinergic urticaria ---- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE...
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
07. Januar 2019 08:00 ET
|
Allakos Inc.
-- 12 of 13 (92%) patients achieved a complete response -- -- Results from 3 additional cohorts expected in the first quarter of 2019 -- REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) --...
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
08. November 2018 16:01 ET
|
Allakos Inc.
-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the...
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
08. Oktober 2018 08:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Second Quarter 2018 Financial Results
29. August 2018 16:01 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24. Juli 2018 08:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...